Table 1.

Ongoing clinical trials testing inhibitors against the leukocyte-enriched PI3Kδ and PI3Kγ isoforms in solid tumors

SponsorPhaseTrial identifierInhibitorCancer type(s)Combination
PI3Kδ
 CRUK and AMGENIINCT02540928AMG-319Head and neck squamous cell carcinoma (nonviral)None (no prior treatment)
 Gilead SciencesINCT02468557IdelalisibPancreatic ductal adenocarcinomaChemotherapy
 TG TherapeuticsINCT02574663TGR-1202Various solid cancersChemotherapy
 IncyteINCT02646748INCB050465Various solid cancersPembrolizumab (anti-PD1)
 IncyteIbNCT02559492INCB050465Various solid cancersINCB039110 (JAK1 inhibitor)
PI3Kγ
 InfinityI/IbNCT02637531IPI-549Non–small cell lung cancer, melanomaPembrolizumab (anti-PD1)